The author presents a bullish thesis on VolitionRx (VNRX), citing Nu.Q Vet Cancer Test expansion into all 50 U.S. states and Asia as a TAM and recurring-revenue catalyst.
VNRX — LONG The author argues VolitionRx is shifting from science to commercial product as Nu.Q Vet Cancer Test expands via Midwest Veterinary Laboratory across all 50 U.S. states starting February 2026 and via Bioguard in Taiwan/China. Management-cited TAM rises from about $100M for the U.S./Europe/Japan to nearly $150M with China, while annual checkups and senior wellness exams could turn the test into recurring revenue. Recent feline lymphoma data and $2.0M funding provide support, but the author flags micro-cap risks and execution risk on the rollouts.
If they can execute on the 50-state US rollout and gain traction in the massive Chinese market, this $36M valuation might look very small in a year.
This Reddit post, published January 20, 2026, features u/Impossible-Hair1343 discussing VNRX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Impossible-Hair1343 · Tickers: VNRX